What are Regenxbio's profit margins?

Regenxbio (RGNX) runs a 59.7% gross margin and a -292.3% operating margin, with a -330.2% net margin.

Where do Regenxbio's ratios come from?

Every ratio is computed from Regenxbio's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.

Regenxbio RGNX Ratios & Valuation

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Profitability
Operating margin	-292.3%-198pp	-94.6%+1.5pp	-96%+9.6pp	-105.7%-5.3pp	-100.4%+180pp
Net margin	-330.2%-216pp	-113.8%-3.5pp	-110.3%+2.4pp	-112.7%-12.1pp	-100.6%+172pp
Returns
Return on equity	-196.4%-89.4pp	-107%-30.1pp	-76.9%-14.4pp	-62.5%-15.1pp	-47.4%+32.1pp
Return on invested capital	-170.6%-94.9pp	-75.7%-14.7pp	-61%-5.0pp	-56%-2.6pp	-53.4%+18.3pp
Efficiency
Asset turnover	0.2×-0.2×	0.4×+0.1×	0.3×0.0×	0.3×0.0×	0.3×+0.1×
Liquidity
Current ratio	2.6×+0.2×	2.4×-0.3×	2.7×-0.5×	3.1×+0.2×	2.9×+0.2×
Leverage
Debt-to-equity	3.4×+2.7×	0.7×+0.2×	0.5×+0.1×	0.4×+0.1×	0.3×0.0×
Per Share
Book value per share	$0.40-79.8%	$1.99-36.2%	$3.12-24.7%	$4.15-22.1%	$5.33+1.6%
Valuation
Market capitalization	$529.38M+24.6%	$728.97M+49.5%	$487.46M+13.0%	$431.33M+20.4%	$358.12M-6.5%
Price / sales	6×+3.3×	4.3×+1.3×	3×+0.3×	2.8×+0.5×	2.3×-2.3×
Price / book	25.1×+23.6×	7.1×+4.1×	3×+1.0×	2×+0.7×	1.3×-0.2×

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Regenxbio.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What are Regenxbio's profit margins?: Regenxbio (RGNX) runs a 59.7% gross margin and a -292.3% operating margin, with a -330.2% net margin.
Where do Regenxbio's ratios come from?: Every ratio is computed from Regenxbio's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.